Bibliographic Details
| Title: |
Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar. |
| Authors: |
Randrianarisoa, Rova Malala Fandresena, Refeno, Valéry, Andrianandrasana, Ny Ony Tiana Florence, Ralison, Fidiarivony, Vololontiana, Hanta Marie Danielle, Rafaramino, Florine |
| Source: |
Hematology; Dec2023, Vol. 28 Issue 1, p1-9, 9p |
| Subject Terms: |
MULTIPLE myeloma, STEM cell transplantation, CHRONIC kidney failure, OVERALL survival, CANCER patients |
| Geographic Terms: |
MADAGASCAR |
| Abstract: |
In Madagascar, the epidemiologic, therapeutic, and evolutionary aspects of multiple myeloma remain poorly understood. Our objectives were to describe the cases, report factors associated with mortality, and estimate patient survival. This was a retrospective descriptive and analytical study conducted in five teaching hospitals in Madagascar: HJRA and CENHOSOA (Antananarivo), CHUPZAGA (Mahajanga), CHUAT (Toamasina) and CHUT (Fianarantsoa). The study included patients diagnosed with multiple myeloma between January 1, 2010 and December 31, 2021. Of the 11,374 cancer patients, 75 (0.66%) had multiple myeloma. The mean age of the patients was 59.9 years (±8.9) and the sex ratio was 1.5. Arterial hypertension was observed in 32% of the patients. The most common symptom of myeloma was bone pain (n = 48; 64%). Forty-six patients (61%) were diagnosed with stage III myeloma and 28 patients (37.3%) with stage IIIA myeloma according to the Durie-Salmon classification. Anemia, renal failure, hypercalcemia and fractures were present in 53%, 37%, 21% and 28% of cases, respectively. Fifty-four patients received specific treatment. The combination of melphalan-prednisone-thalidomide was used in 79.63% of cases, and one patient had received autologous stem cell transplantation. Eleven patients (14.67%) died. Chronic kidney disease (p = 0.009), smoking (p = 0.028) and two associated comorbidities (p = 0.035) were associated with mortality. The median overall survival was 45.5 months. Patient survival is shorter than reported in the literature. The high mortality rate is due to comorbidities and limited access to recommended therapies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Hematology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
